De-an  Guo

Dr. De-an Guo

Shanghai Research Center for Modernization of Traditional Chinese Medicine, National Engineering Laboratory for TCM Standardization Technology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 501 Haike Road, Shanghai 201203, China

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2014 in Phytochemistry
Verified
Journal Article
Closed access
WYWen-Zhi Yang
Wen-Zhi Yang
YHYing Hu
Ying Hu
WWWan-Ying Wu
Wan-Ying Wu
MYMin Ye
Min Ye
De-an  GuoDe-an Guo
De-an Guo

1 July 2017 in Acta Pharmaceutica Sinica B
Verified
Journal Article
Open access
WYWenzhi Yang
Wenzhi Yang
YZYibei Zhang
Yibei Zhang
WWWanying Wu
Wanying Wu
LHLuqi Huang
Luqi Huang
De-an  GuoDe-an Guo
De-an Guo
CLChangxiao Liu
Changxiao Liu
Traditional Chinese medicine (TCM) has played a pivotal role in maintaining the health of Chinese people and is now gaining increasing acceptance around the global scope. However, TCM is confronting more and more concerns with respect to its quality. The intrinsic "multicomponent and multitarget" feature of TCM necessitates the establishment of a unique quality and bioactivity evaluation system, which is different from that of the Western medicine. However, TCM is investigated essentially as "herbal medicine" or "natural product", and the pharmacopoeia quality monographs are actually chemical-markers-based, which can ensure the consistency only in the assigned chemical markers, but, to some extent, have deviated from the basic TCM theory. A concept of "quality marker" (Q-marker), following the "property-effect-component" theory, is proposed. The establishment of Q-marker integrates multidisciplinary technologies like natural products chemistry, analytical chemistry, bionics, chemometrics, pharmacology, systems biology, and pharmacodynamics, etc. Q-marker-based fingerprint and multicomponent determination conduce to the construction of more scientific quality control system of TCM. This review delineates the background, definition, and properties of Q-marker, and the associated technologies applied for its establishment. Strategies and approaches for establishing Q-marker-based TCM quality control system are presented and highlighted with a few TCM examples.

22 August 2011 in Journal of Cellular Physiology
Verified
Journal Article
Closed access
PDF file
WWWen‐Bo Wang
Wen‐Bo Wang
LFLi‐Xing Feng
Li‐Xing Feng
QYQing‐Xi Yue
Qing‐Xi Yue
WWWan‐Ying Wu
Wan‐Ying Wu
SGShu‐Hong Guan
Shu‐Hong Guan
De-an  GuoDe-an Guo
De-an Guo

13 June 2013 in BMC Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
QXQihe Xu
Qihe Xu
Rudolf BauerRudolf Bauer
Rudolf Bauer
BHBruce M Hendry
Bruce M Hendry
TFTai-Ping Fan
Tai-Ping Fan
ZZZhong-Zhen Zhao
Zhong-Zhen Zhao
PHPeter J Hylands
Peter J Hylands
Traditional Chinese medicine (TCM) is an integral part of mainstream medicine in China. Due to its worldwide use, potential impact on healthcare and opportunities for new drug development, TCM is also of great international interest. Recently, a new era for modernisation of TCM was launched with the successful completion of the Good Practice in Traditional Chinese Medicine Research in the Post-genomic Era (GP-TCM) project, the European Union’s Seventh Framework Programme (FP7) coordination action on TCM research. This 3.5-year project that involved inputs from over 200 scientists resulted in the production of 20 editorials and in-depth reviews on different aspects of TCM that were published in a special issue of Journal of Ethnopharmacology (2012; volume 140, issue 3). In this narrative review, we aim to summarise the findings of the FP7 GP-TCM project and highlight the relevance of TCM to modern medicine within a historical and international context. Advances in TCM research since the 1950s can be characterised into three phases: Phase I (1950s-1970s) was fundamental for developing TCM higher education, research and hospital networks in China; Phase II (1980s-2000s) was critical for developing legal, economic and scientific foundations and international networks for TCM; and Phase III (2011 onwards) is concentrating on consolidating the scientific basis and clinical practice of TCM through interdisciplinary, interregional and intersectoral collaborations. Taking into account the quality and safety requirements newly imposed by a globalised market, we especially highlight the scientific evidence behind TCM, update the most important milestones and pitfalls, and propose integrity, integration and innovation as key principles for further modernisation of TCM. These principles will serve as foundations for further research and development of TCM, and for its future integration into tomorrow’s medicine.

1 June 2020 in Journal of Pharmaceutical and Biomedical Analysis
Verified
Journal Article
Closed access
YLYun Li
Yun Li
YSYao Shen
Yao Shen
CYChang-Liang Yao
Chang-Liang Yao
De-an  GuoDe-an Guo
De-an Guo

11 May 2005 in Rapid Communications in Mass Spectrometry
Verified
Journal Article
Closed access
PDF file
MYMin Ye
Min Ye
YYYuning Yan
Yuning Yan
De-an  GuoDe-an Guo
De-an Guo